In contrast, quantitative IHC analysis of tumor tissues from cancer patients shows that anti-CTLA-4 immunotherapy using ipilimumab or tremelimumab (anti-human CTLA-4 hIgG2) did not deplete Foxp3+cells in human tumors [17]. The gene discussed is CTLA4; the disease is neoplasm.